When combined with liposomal doxorubicin (Doxil), an FDA-approved cancer nanodrug, Pgp-targeted NIR-PIT improves the therapeutic effect of Doxil by depleting multidrug resistant (MDR) cancer cells and increasing the tumor penetration of Doxil 71. Here, PGP is linked to neoplasm.